Your browser doesn't support javascript.
In-hospital outcomes of COVID-19 infection in patients with underlying cardiovascular disease.
Changal, Khalid; Mack, Sean; Veria, Spiro; Paternite, David; Bashir, Rehana; Patel, Mitra; Ali, Muhammad; Nazir, Salik; Mir, Tanveer; Sheikh, Mujeeb; Ramanathan, P Kasi.
  • Changal K; Cardiovascular Medicine, University of Toledo, OH, USA.
  • Mack S; Department of Medicine, University of Toledo College of Medicine and Life Sciences, USA.
  • Veria S; Department of Medicine, University of Toledo College of Medicine and Life Sciences, USA.
  • Paternite D; Department of Medicine, University of Toledo College of Medicine and Life Sciences, USA.
  • Bashir R; Cardiovascular Medicine, University of Connecticut School of Dental Medicine, CT, USA.
  • Patel M; Department of Medicine, University of Toledo College of Medicine and Life Sciences, USA.
  • Ali M; Internal Medicine, University of Toledo, OH, USA.
  • Nazir S; Cardiovascular Medicine, University of Toledo, OH, USA.
  • Mir T; Internal Medicine, Detroit Medical Center, Wayne State University, MI, USA.
  • Sheikh M; Cardiovascular Medicine, Promedica Toledo Hospital, OH, USA.
  • Ramanathan PK; Cardiovascular Medicine, Promedica Toledo Hospital, OH, USA.
Expert Rev Cardiovasc Ther ; 19(9): 871-876, 2021 Sep.
Article in English | MEDLINE | ID: covidwho-1364675
ABSTRACT

BACKGROUND:

The effects of cardiovascular comorbidities on outcomes in COVID-19 hospitalized patients has not been well studied.

METHODS:

This is a hospital-based study evaluating the effects of CVD on the outcomes in patients admitted with COVID-19. Clinical outcomes were studied in patients with and without CVD.

RESULTS:

Eighty-seven patients had CVD, and 193 patients had no history of CVD. Ischemic heart disease was the most common CVD (63%). When compared with patients with no CVD, those with CVD had higher mortality (29% vs 9%, p < 0.001), discharge to a skilled nursing facility (SNF) (36% vs 15%, p < 0.001), and change of code status to 'do not resuscitate' (41% vs 14%, p < 0.001). The odds for mortality were high with ischemic heart disease (OR 3.6, 95% CI 1.8-7.3, p < 0.001), and systolic heart failure (OR 3.8,95% CI 1.2-12.3, p = 0.02). Patients in the CVD group were more likely to have incident atrial fibrillation (22% vs 3%, p < 0.001), type 2 Mi (17% vs 6%, p = 0.002), high BNP (57% vs 14%, p < 0.001), acute kidney injury (64% vs 29%, p < 0.001), and any type of circulatory shock (27% vs 12%, p = 0.001).

CONCLUSION:

CVD is associated with increased mortality, myocardial injury, arrhythmias, and discharges to an SNF.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Cardiovascular Diseases / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study Limits: Humans Language: English Journal: Expert Rev Cardiovasc Ther Journal subject: Vascular Diseases / Cardiology / Therapeutics Year: 2021 Document Type: Article Affiliation country: 14779072.2021.1970532

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Cardiovascular Diseases / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study Limits: Humans Language: English Journal: Expert Rev Cardiovasc Ther Journal subject: Vascular Diseases / Cardiology / Therapeutics Year: 2021 Document Type: Article Affiliation country: 14779072.2021.1970532